In Europe, TEPKINLY® (epcoritamab) combined with lenalidomide and rituximab (R2) has become the initial and sole bispecific treatment sanctioned for managing relapsed or refractory follicular lymphoma in the second-line scenario. This regimen provides a chemotherapy-free alternative. The Phase 3 EPCORE® FL-1 trial led to this approval.